Although the survival rate of natalizumab-associated progressive multifocal leukoencephalopathy (PML) is better than PML in HIV patients, long-term they may need some assistance and care, Ralf Gold, Ruhr University Bochum in Germany, said at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.
Although the survival rate of natalizumab-associated progressive multifocal leukoencephalopathy (PML) is better than PML in HIV patients, long-term they may need some assistance and care, according to Ralf Gold, professor in the Department of Neurology at St. Josef-Hospital at Ruhr University Bochum in Germany.
Speaking at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts, from September 10-13, Gold looked at the most common culprits of PML in MS patients — natalizumab, fingolimod, and fumarate — as well as long-term follow-up for these patients.
PML has now affected more than 450 MS patients receiving long-term natalizumab; unfortunately, since PML is not a reportable disease, there are no exact numbers. In addition to natalizumab, there are carry over effects when patients switch to fingolimod or fumarates, particularly when the initial signs of PML were overlooked, Gold explained.
While there is no clear evidence of PML primarily associated with fingolimod, this may change down the line, he said. For instance, in Germany, they have encountered cases where an old mixture of fumarates, known as fumaderm, is associated with rare PML cases.
While the gross survival rate in natalizumab-associated PML is approximately 80%, long-term function can be affected depending on the site of infection. Using the Karnofsky Performance Status scale, Gold showed that when the patient is fully active before PML, they have a score of 80 to 100; during PML onset the score drops to 60, at which point a patient may need some assistance; and during the onset of immune reconstitution inflammatory syndrome the score drops further to 35, which would require constant assistant, possibly in a nursing home.
However, the score then climbs back to 50-60. This might constitute some assistance and care, and many survivors with such a score do not go back to work.
“You can treat PML, but the outcome, sometimes, is fate,” Gold said.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More